Cargando…

The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals

Fifty years ago several thousand children were born with severe limb defects after their mothers had been given thalidomide in pregnancy. This tragedy caused procedures for licensing new medicines to become much stricter. Where, nevertheless, significant side effects were found it became common to s...

Descripción completa

Detalles Bibliográficos
Autor principal: Lachmann, P.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516063/
https://www.ncbi.nlm.nih.gov/pubmed/22908318
http://dx.doi.org/10.1093/qjmed/hcs148
_version_ 1782252272289316864
author Lachmann, P.J.
author_facet Lachmann, P.J.
author_sort Lachmann, P.J.
collection PubMed
description Fifty years ago several thousand children were born with severe limb defects after their mothers had been given thalidomide in pregnancy. This tragedy caused procedures for licensing new medicines to become much stricter. Where, nevertheless, significant side effects were found it became common to sue for damages. These consequences have caused possibly an even greater disaster damaging many more people and threatening ruin to health services everywhere. The huge increase in both time and cost in bringing medicines to market is increasing their price to unsupportable levels; and only wealthy companies are now able to do so. This requires reform as does litigation for ‘statistical’ harmful effects.
format Online
Article
Text
id pubmed-3516063
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-35160632012-12-06 The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals Lachmann, P.J. QJM Original Papers Fifty years ago several thousand children were born with severe limb defects after their mothers had been given thalidomide in pregnancy. This tragedy caused procedures for licensing new medicines to become much stricter. Where, nevertheless, significant side effects were found it became common to sue for damages. These consequences have caused possibly an even greater disaster damaging many more people and threatening ruin to health services everywhere. The huge increase in both time and cost in bringing medicines to market is increasing their price to unsupportable levels; and only wealthy companies are now able to do so. This requires reform as does litigation for ‘statistical’ harmful effects. Oxford University Press 2012-12 2012-08-19 /pmc/articles/PMC3516063/ /pubmed/22908318 http://dx.doi.org/10.1093/qjmed/hcs148 Text en © The Author 2012. Published by Oxford University Press on behalf of the Association of Physicians. http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Original Papers
Lachmann, P.J.
The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals
title The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals
title_full The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals
title_fullStr The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals
title_full_unstemmed The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals
title_short The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals
title_sort penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516063/
https://www.ncbi.nlm.nih.gov/pubmed/22908318
http://dx.doi.org/10.1093/qjmed/hcs148
work_keys_str_mv AT lachmannpj thepenumbraofthalidomidethelitigationcultureandthelicensingofpharmaceuticals
AT lachmannpj penumbraofthalidomidethelitigationcultureandthelicensingofpharmaceuticals